Links on this page relate to myelofibrosis.
General MPN information is at the main MPN guidelines and articles page.
Myelofibrosis (MF) specific information
- Impact of CALR mutations on treatment and survival outcomes in MF during ruxolitinib therapy, Nature, 2025
- Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group, Letter, Leukemia, 2024
- Outcomes and characteristics of nonmelanoma skin cancers in patients with myeloproliferative neoplasms on ruxolitinib, Letter to Blood, 2024
- Management of Patients with Early Myelofibrosis: A Discussion of Best Practices, Review paper, 2024
- Myelofibrosis management in routine clinical practice with a focus on patients with cytopenias: recommendations from a global consensus group, Leukemia, 2024
- Diagnosis and evaluation of prognosis of myelofibrosis: A British Society for Haematology Guideline, BJH 2023
- The management of myelofibrosis: A British Society for Haematology Guideline, Companion Guideline, BJH, 2023
- Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology (myelofibrosis focus)
- Myelofibrosis, Blood, 2023
- Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management, AJH, 2023
- Blast phase MPN: contemporary review and 2024 treatment algorithm, Nature – Blood Cancer Journal, 2023
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety, Journal of Hematology and Oncology, 2023
- Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy, Leukemia and Lymphoma, 2023
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia, Journal of Hematology and Oncology, 2022
- A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study, Therapeutic Advances in Hematology, 2022
Myelofibrosis Stem Cell Transplant information
- Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study, Blood Advances, 2024
- Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group, The Lancet Hematology. 2024
- Impact of TP53 on outcomes of patients with myelofibrosis undertaking hematopoetic stem cell transplants, Blood, 2023
- How I treat transplant-eligible patients with myelofibrosis, Blood, 2023
- Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis, Haematologica, 2023
- Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial, Blood Advances, 2023
- Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms:
A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, AJH, 2023 - Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis, AJH, 2022
- MPN Research Foundation (USA) – patient specific information about stem cell transplants and timing
- Survival following allogeneic transplant in patients with myelofibrosis